Skip to main content

Table 3 Sensitivity analysis, total annual cost-of-illness (Euros, millions) of hypertension in the presence and absence of MetS; 2008

From: Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model

 

Germany

Spain

Italy

Baseline

   

   Presence

24,427

1,908

4,877

   Absence

5,341

2,683

5,956

Type 2 diabetes; including only incident type 2 diabetes

   

   Presence

8,753

1,050

1,775

   Absence

3,382

2,115

3,876

Proportion treated; assume 58% hypertensive subjects were treated in Spain

   

   Presence

NA

2,010

NA

   Absence

NA

3,058

NA

Continuation rate; vary by 20% above/below the mean

   

   + 20% Presence

24,418

1,913

4,895

   + 20% Absence

5,357

2,707

6,035

   - 20% Presence

24,406

1,898

4,850

   - 20% Absence

5,302

2,635

5,831

Costs; vary by 20% above/below the mean

Drug costs

   

   + 20% Presence

24,553

1,928

4,929

   + 20% Absence

5,423

4,329

6,147

   - 20% Presence

24,247

1,886

4,825

   - 20% Absence

5,224

2,603

5,762

CVD costs

   

   + 20% Presence

25,481

2,049

5,041

   + 20% Absence

5,682

2,934

6,276

   - 20% Presence

23,373

1,769

4,714

   - 20% Absence

5,000

2,431

5,637

Type 2 diabetes costs

   

   + 20% Presence

27,743

2,102

5,573

   + 20% Absence

5,735

2,803

6,392

   - 20% Presence

21,112

1,715

4,183

   - 20% Absence

4,948

2,564

5,521